Monoamine Oxidase Inhibitors
"Monoamine Oxidase Inhibitors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A chemically heterogeneous group of drugs that have in common the ability to block oxidative deamination of naturally occurring monoamines. (From Gilman, et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 8th ed, p414)
| Descriptor ID |
D008996
|
| MeSH Number(s) |
D27.505.519.389.616
|
| Concept/Terms |
Monoamine Oxidase Inhibitors- Monoamine Oxidase Inhibitors
- Inhibitors, Monoamine Oxidase
- Monoamine Oxidase Inhibitor
- Inhibitor, Monoamine Oxidase
- MAO Inhibitors
- Inhibitors, MAO
|
Below are MeSH descriptors whose meaning is more general than "Monoamine Oxidase Inhibitors".
Below are MeSH descriptors whose meaning is more specific than "Monoamine Oxidase Inhibitors".
This graph shows the total number of publications written about "Monoamine Oxidase Inhibitors" by people in this website by year, and whether "Monoamine Oxidase Inhibitors" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 1 | 0 | 1 |
| 1996 | 1 | 0 | 1 |
| 1997 | 1 | 0 | 1 |
| 1998 | 0 | 2 | 2 |
| 2000 | 0 | 1 | 1 |
| 2007 | 0 | 1 | 1 |
| 2015 | 1 | 1 | 2 |
| 2016 | 3 | 0 | 3 |
| 2017 | 2 | 0 | 2 |
| 2018 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Monoamine Oxidase Inhibitors" by people in Profiles.
-
Acute hypertensive crisis and severe headache after concurrent use of armodafinil and tranylcypromine: Case report and review of the literature. J Neurol Sci. 2018 10 15; 393:1-3.
-
Inhibition of human monoamine oxidase A and B by flavonoids isolated from two Algerian medicinal plants. Phytomedicine. 2018 Feb 01; 40:27-36.
-
Longer Duration of MAO-B Inhibitor Exposure is Associated with Less Clinical Decline in Parkinson's Disease: An?Analysis?of?NET-PD LS1. J Parkinsons Dis. 2017; 7(1):117-127.
-
Isolation of Acacetin from Calea urticifolia with Inhibitory Properties against Human Monoamine Oxidase-A and -B. J Nat Prod. 2016 10 28; 79(10):2538-2544.
-
Rasagiline for mild cognitive impairment in Parkinson's disease: A placebo-controlled trial. Mov Disord. 2016 05; 31(5):709-14.
-
Effects of Monoamine Oxidase Inhibition on the Reinforcing Properties of Low-Dose Nicotine. Neuropsychopharmacology. 2016 08; 41(9):2335-43.
-
BDNF levels are increased by aminoindan and rasagiline in a double lesion model of Parkinson?s disease. Brain Res. 2016 Jan 15; 1631:34-45.
-
Effects of MAO inhibition and a combination of minor alkaloids, ?-carbolines, and acetaldehyde on nicotine self-administration in adult male rats. Drug Alcohol Depend. 2015 Oct 01; 155:243-52.
-
MAO-A-induced mitogenic signaling is mediated by reactive oxygen species, MMP-2, and the sphingolipid pathway. Free Radic Biol Med. 2007 Jul 01; 43(1):80-9.
-
Pharmacologic characteristics of ideal antidepressants in the 21st century. J Clin Psychiatry. 2000; 61 Suppl 11:4-8.